STK11 and melanoma: The NR4A1-targeting compound, ethyl 2-[2,3,4-trimethoxy-6-(1-octanoyl)phenyl] acetate (TMPA) reduces blood glucose by disrupting NR4A1-LKB1 interaction and activating AMPKα50, and 1-(3,4,5-trihydroxyphenyl)nonan-1-one (THPN) induces autophagic cell death of melanoma through the mitochondrial signaling pathway51.